Log in

NASDAQ:CDXSCodexis Stock Price, Forecast & News

$12.42
-0.19 (-1.51 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.12
Now: $12.42
$12.65
50-Day Range
$10.33
MA: $11.23
$12.61
52-Week Range
$8.43
Now: $12.42
$19.32
Volume380,854 shs
Average Volume458,917 shs
Market Capitalization$733.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.64
Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Read More
Codexis logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$68.46 million
Book Value$1.68 per share

Profitability

Net Income$-11,940,000.00

Miscellaneous

Employees132
Market Cap$733.03 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.

Codexis (NASDAQ:CDXS) Frequently Asked Questions

How has Codexis' stock been impacted by COVID-19 (Coronavirus)?

Codexis' stock was trading at $10.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDXS shares have increased by 22.7% and is now trading at $12.42. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Codexis?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Codexis.

When is Codexis' next earnings date?

Codexis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Codexis.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) posted its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. The biotechnology company earned $14.67 million during the quarter, compared to analyst estimates of $12.53 million. Codexis had a negative net margin of 21.40% and a negative return on equity of 14.24%. View Codexis' earnings history.

What price target have analysts set for CDXS?

2 Wall Street analysts have issued 12-month price targets for Codexis' stock. Their forecasts range from $21.00 to $21.00. On average, they expect Codexis' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 69.1% from the stock's current price. View analysts' price targets for Codexis.

Has Codexis been receiving favorable news coverage?

News headlines about CDXS stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Codexis earned a news impact score of -1.4 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutCodexis.

Who are some of Codexis' key competitors?

What other stocks do shareholders of Codexis own?

Who are Codexis' key executives?

Codexis' management team includes the following people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 55)
  • Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 66)
  • Dr. James J. Lalonde, Sr. VP of R&D (Age 58)
  • Ms. Laurie Heilmann, Sr. VP of Bus. Devel. & Marketing
  • Prof. Gerhard N. Mayr, Special Advisor to the Board (Age 73)

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (6.93%), BlackRock Inc. (6.10%), William Blair Investment Management LLC (4.06%), Wells Fargo & Company MN (3.49%), Vivo Capital LLC (2.53%) and Janus Henderson Group PLC (2.51%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Patrick Y Yang and Thomas R Baruch. View institutional ownership trends for Codexis.

Which major investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, Wells Fargo & Company MN, JPMorgan Chase & Co., Blair William & Co. IL, Spark Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., UBS Group AG, and Morgan Stanley. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, and Thomas R Baruch. View insider buying and selling activity for Codexis.

Which major investors are buying Codexis stock?

CDXS stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, William Blair Investment Management LLC, Ziegler Capital Management LLC, Baillie Gifford & Co., Assenagon Asset Management S.A., Tarsadia Capital LLC, Aviva PLC, and Essex Investment Management Co. LLC. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang. View insider buying and selling activity for Codexis.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $12.42.

How big of a company is Codexis?

Codexis has a market capitalization of $733.03 million and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.

What is Codexis' official website?

The official website for Codexis is www.codexis.com.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.